Clinical Factors and Gene Expression Analysis for Prognosis in Tissue Samples From Patients With AIDS-Related Primary Effusion Lymphoma

PRIMARY OBJECTIVES:

I. Identify baseline clinical characteristics and treatment strategies in patients with
AIDS-associated primary effusion lymphoma (PEL) that correlate with long-term survival (>= 2
years). (Primary clinical objective) II. Identify differentially expressed genes in PEL that
are associated with long-term survival (>= 2 years). (Primary genomic objective)

OUTLINE:

Medical chart review is performed and patient information is collected regarding human
immunodeficiency virus human immunodeficiency virus (HIV)/AIDS medical history, staging of
AIDS related malignancy, and type of treatment. Previously collected tissue samples are
analyzed via ribonucleic acid (RNA) sequencing and microarray.

Inclusion Criteria:

- Patients diagnosed with primary effusion lymphoma (HIV seropositive or negative) on or
after January 1, 1998 on whom survival status at 2 years post PEL diagnosis is
available

- Participants may be enrolled to either or both the clinical or genomic portions of the
study

- The minimum data required to be able to include a subject for analysis of clinical
prognostic factors are:

- HIV status, and for HIV subjects include cluster of differentiation (CD)4 count,
HIV viral load closest to time of diagnosis

- Age at PEL diagnosis

- Gender

- Stage at diagnosis

- Treatment of PEL

- Response to treatment

- Survival status at 2 years

- Pathology slides (or paraffin block) for central review

- The minimum data required to be able to include a subject for analysis of genomic
prognostic factors are:

- Availability of a pathologic specimen of PEL that will be submitted for genomic
analysis

- Survival status at 2 years

Exclusion Criteria:

- Patients who do not fulfill the criteria as listed above are ineligible